Best Practices in the Coadministration of Respiratory Vaccines
July 11th 2025Panelists discuss strategies to address patient hesitancy around receiving multiple vaccines—flu, COVID-19, and RSV—simultaneously during the fall, emphasizing CDC recommendations for co-administration, educating patients about manageable adverse effects, tailoring conversations to individual concerns, and encouraging year-round RSV vaccination to maximize protection and reduce missed opportunities.
Optimizing Multidisciplinary Care in RSV Vaccination Efforts
July 11th 2025Panelists discuss how community pharmacies have become trusted hubs for adult vaccinations, with pharmacists not only administering vaccines but also educating patients and coordinating with other health care providers to ensure clear, unified messaging; they emphasize the importance of collaboration, empowering pharmacists to use clinical judgment, and actively navigating insurance challenges to improve vaccine access and public health outcomes.
Building Trust With Vaccine-Hesitant Patients
July 11th 2025Panelists discuss that building trust with vaccine-hesitant patients requires pharmacists to slow down, listen empathetically, and ask open-ended questions to understand individual concerns; by addressing specific fears with clear, tailored information and practicing cultural sensitivity, pharmacists can foster ongoing, respectful dialogue that gradually encourages vaccine acceptance.
Common Causes of RSV Vaccine Hesitancy
July 11th 2025Panelists discuss vaccine hesitancy surrounding the new RSV vaccine, highlighting factors such as uncertainty about safety and effectiveness, cost concerns, limited health literacy, language barriers, and lingering skepticism fueled by the COVID-19 pandemic, emphasizing how pharmacists can address these issues through tailored education, insurance guidance, and culturally sensitive communication to build patient trust and improve vaccine uptake.
Additional Clinical Considerations for RSV Vaccination
July 11th 2025Panelists discuss recent safety updates on RSV vaccines, including a rare potential risk of Guillain-Barré syndrome (GBS) in older adults receiving recombinant vaccines, emphasizing that benefits outweigh risks and highlighting the pharmacist’s role in educating patients about common adverse effects, recognizing early signs of rare adverse events, and navigating regulatory guidance to support safe, informed vaccination decisions.
Pertinent Information for Shared Decision-Making
July 11th 2025Panelists discuss that effective shared clinical decision-making for RSV vaccination begins with clear, simple education about RSV’s risks and vaccine benefits, encourages patient questions, and involves transparent communication about how vaccines work and their safety; they emphasize that pharmacists already practice this approach routinely and should confidently use it to support informed patient choices and improve vaccine uptake.
Ideal Patient Populations for RSV Vaccination
July 11th 2025Panelists discuss that pharmacies should prioritize practical workflow and patient management over clinical preference when administering RSV vaccines, since all FDA-approved vaccines are equally recommended; focusing on factors like preparation ease, storage, patient eligibility, and insurance helps streamline operations and promote timely vaccination without delays due to product choice or patient preference.
Key Differences Between FDA-Approved RSV Vaccines
July 11th 2025Panelists discuss the 3 FDA-approved RSV vaccines for high-risk adults—2 recombinant protein-based (1 adjuvanted, 1 bivalent) and one mRNA-based—highlighting differences in formulation, mechanism, and preparation, and emphasizing the importance of education to address misconceptions and guide appropriate vaccine selection.
Targeting Patients at Risk for Severe RSV Disease
July 11th 2025Panelists discuss how pharmacies can boost RSV vaccination rates in high-risk adults by leveraging patient visits—especially during other immunizations—using integrated immunization registries and medication profiles to identify eligible patients, involving pharmacy technicians in vaccine conversations, and employing presumptive recommendation strategies to increase acceptance and awareness.
Implied Vaccine Burden and Associated Misinformation
July 11th 2025Panelists discuss how pharmacists can address patients’ growing vaccine fatigue and misconceptions—such as underestimating RSV’s severity in adults or believing it requires multiple doses—by providing clear, consistent education and emphasizing that a single RSV vaccine offers protection against serious illness in high-risk populations.
Exploring High-Risk Populations for RSV Complications
July 11th 2025Panelists discuss how pharmacists can identify high-risk adults for severe RSV—such as those with chronic conditions or advanced age—by reviewing medication profiles, and how they can overcome barriers like limited awareness and workflow challenges to drive vaccine uptake through education, accessibility, and recent policy-supported coverage.
Pathophysiology and Complications Associated With Respiratory Syncytial Virus (RSV)
July 11th 2025Panelists discuss clinical strategies to improve RSV vaccine uptake in high-risk adults by reviewing disease severity, comparing approved vaccines, and emphasizing the pharmacist’s pivotal role in patient education and vaccine advocacy to overcome hesitancy and increase protection in vulnerable populations.
Milestones That Matter: Using Molecular and Clinical Benchmarks to Guide CML Therapy
July 10th 2025An expert discusses how achieving molecular and clinical milestones early in chronic myeloid leukemia (CML) treatment reduces transformation risk, enables potential treatment discontinuation after specific criteria are met, and helps identify treatment resistance requiring mutational analysis or adherence assessment.
Breaking Through Misconceptions: How Pharmacists Can Shift the Conversation for Vaccines
July 10th 2025An expert discusses how pharmacists can overcome common vaccination barriers by addressing misconceptions about vaccine necessity, making strong provider recommendations, and educating patients about mild adverse effects while building trust through consistent communication.
Leveraging Trial Data to Guide Frontline TKI Use
July 10th 2025An expert discusses how landmark trials such as ASC4FIRST, ENESTnd, and BFORE provide evidence for frontline tyrosine kinase inhibitor (TKI) selection, with asciminib showing superior tolerability and lower discontinuation rates (4.5%) compared with first-generation (11%) and second-generation TKIs (9.8%).
Role of Pharmacists in Addressing Vaccine Safety Concerns
July 10th 2025An expert discusses how pharmacists can evaluate patients with prior adverse vaccine reactions by distinguishing between mild local reactions and serious anaphylactic responses, then recommending supervised vaccination or medical center administration when appropriate.
Comparative Perspectives: TD Management vs Other Movement Disorders
July 7th 2025Panelists discuss how the long-term management of movement disorders like tardive dyskinesia, Parkinson disease, and Huntington disease requires individualized, patient-centered care that adapts to changing health and tolerance over time, aiming to maintain function and quality of life despite differing disease trajectories and treatment challenges.
Sustained Benefits of Long-Term VMAT2 Inhibitor Therapy in Tardive Dyskinesia
July 7th 2025Panelists discuss how open-label extension studies of VMAT2 inhibitors demonstrate sustained efficacy, tolerability, and patient retention in long-term treatment of tardive dyskinesia—including in older adults—highlighting their potential to improve quality of life despite manageable adverse effects.
Navigating CDC Recommendations for Pneumococcal Vaccines and Contraindications
July 3rd 2025An expert discusses how pharmacists should follow CDC immunization schedules for different age groups and use shared clinical decision-making for patients with prior vaccination history, while considering contraindications primarily related to severe allergic reactions to vaccine components.
Breaking Down Pneumococcal Conjugate vs Polysaccharide Vaccines
July 3rd 2025An expert discusses how the 5 FDA-approved pneumococcal vaccines differ, with newer conjugate vaccines like PCV20 and PCV21 offering broader serotype coverage and better immune memory compared with the older polysaccharide vaccine, though geographic factors may influence vaccine selection.
Precision and Protection: Inside Cone Health’s Robotic Compounding Program
July 2nd 2025Pharmacy leaders from Cone Health discuss how robotic compounding technologies have improved safety, accuracy, and reliability in hazardous and sterile medication preparation across oncology and acute care settings.